Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 19Lymphoma 17Lymphoma, Large B-Cell, Diffuse 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 14Hodgkin Disease 13Multiple Myeloma 12Lymphoma, Mantle-Cell 12Lymphoma, Follicular 12Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 9Glioblastoma 9Lymphoma, B-Cell, Marginal Zone 8Burkitt Lymphoma 8Brain Neoplasms 8Sezary Syndrome 7Neoplasms 7Lymphoma, T-Cell, Cutaneous 7Leukemia 7Congenital Abnormalities 7Unspecified Adult Solid Tumor, Protocol Specific 6Recurrence 6Neuroblastoma 6Mycosis Fungoides 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Large-Cell, Anaplastic 6Breast Neoplasms, Male 6Sarcoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5

Interventions

Ipilimumab 16incomplete Freund's adjuvant 9Nivolumab 9sargramostim 6Temozolomide 6Dacarbazine 6montanide ISA 51 5MART-1 Antigen 5Blood Specimen Collection 5pembrolizumab 4Ranibizumab 4Melphalan 4Interleukin-2 4Carboplatin 4CTLA-4 Antigen 4Thalidomide 3Surveys and Questionnaires 3MAGEA3 protein, human 3Granulocyte-Macrophage Colony-Stimulating Factor 3AZD 6244 3sotrastaurin 2relatlimab 2gp100 Melanoma Antigen 2fludarabine phosphate 2fludarabine 2entinostat 2aflibercept 2Taxes 2Sunitinib 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Uveal Melanoma × Vorinostat × Clear all
NCT00121225 2019-01-29

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
32 enrolled 11 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡